Skip to main content

RARA KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 7.

Be the first to review this product! Submit a review

Images

Western blot - Human RARA (Retinoic Acid Receptor alpha) knockout HeLa cell line (AB265176), expandable thumbnail
  • Sanger Sequencing - Human RARA (Retinoic Acid Receptor alpha) knockout HeLa cell line (AB265176), expandable thumbnail

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 7

Alternative names

NR1B1, Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein, Nuclear receptor subfamily 1 group B member 1, Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form, RAR, RAR-alpha, RARA_HUMAN, RARalpha1, Retinoic acid nuclear receptor alpha variant 1, Retinoic acid nuclear receptor alpha variant 2, Retinoic acid receptor alpha, Retinoic acid receptor alpha polypeptide

Recommended products

RARA KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 7.

Key facts

Cell type

HeLa

Form

Liquid

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 7

Antibiotic resistance

Puromycin 1µg/mL

Disease

Adenocarcinoma

Concentration
Loading...

Properties

Gene name

RARA

Gene editing type

Knockout

Gene editing method

CRISPR technology

Knockout validation

Sanger Sequencing

Zygosity

Homozygous

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines

  • All seeding densities should be based on cell counts gained by established methods.

  • A guide seeding density of 2x104 cells/cm2 is recommended.

  • Cells should be passaged when they have achieved 80-90% confluence.

Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions

Dry Ice

Appropriate long-term storage conditions

-196°C

Notes

Recommended control: Human wild-type HeLa cell line (Human wild-type HeLa cell line ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Retinoic Acid Receptor alpha (RARA) a member of the nuclear receptor superfamily functions as a transcription factor activated by retinoic acid. Commonly referenced in literature RARA has an approximate molecular mass of 50 kDa. It is expressed in a variety of tissues including the liver the lung and the immune system. By forming heterodimers with retinoid X receptors RARA regulates the transcription of genes linked to cell differentiation proliferation and apoptosis.

Biological function summary

RARA plays an essential role in mediating the effects of retinoic acid in the body. It is part of a larger receptor complex that interacts with co-regulators to modulate gene expression. This process is significant for embryonic development and the maintenance of normal physiological functions. Through its action RARA contributes to the proper development of organs and is critical for maintaining immune homeostasis and enabling the cellular response to environmental changes.

Pathways

RARA's activity impacts important signaling routes such as the retinoic acid signaling pathway and the Wnt signaling pathway. It collaborates with proteins like retinoid X receptors (RXRs) and other nuclear receptors to influence gene expression processes. These pathways maintain cellular differentiation and tissue homeostasis demonstrating RARA's integrative role in cellular signaling and communication.

Associated diseases and disorders

RARA's dysregulation has been linked to acute promyelocytic leukemia (APL) and some autoimmune diseases. In APL aberrant fusion proteins involving RARA disrupt normal transcriptional regulation leading to malignant transformation. Additionally the interaction of RARA with proteins such as promyelocytic leukemia protein (PML) further influences the disease's development. Research on these associations highlights the therapeutic potential of targeting RARA activities for disease intervention and treatment strategies.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com